MedicaidJanuary 17, 2024
Clinical Criteria updates — September 2023
On September 21, 2023, and October 4, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Anthem Blue Cross (Anthem). These policies were developed, revised, or reviewed to support clinical coding edits.
Visit Clinical Criteria to search for specific policies. For questions or additional information, use this email.
Please see the explanation/definition for each category of Clinical Criteria below:
- New: Newly published criteria
- Revised: Addition or removal of medical necessity requirements, new document number
- Updates Marked with an asterisk (*) notate that the criteria may be perceived as more restrictive
Please share this notice with other providers in your practice and office staff.
Please note:
- The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
- This notice is meant to inform the provider of new or revised criteria that has been adopted by Anthem only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.
Effective date | Clinical Criteria number | Clinical Criteria title | New or revised |
April 25, 2024 | *CC-0248 | Elrexfio (elranatamab-bcmm) | New |
April 25, 2024 | *CC-0249 | Talvey (talquetamab-tgvs) | New |
April 25, 2024 | *CC-0250 | Veopoz (pozelimab-bbfg) | New |
April 25, 2024 | *CC-0251 | Ycanth (cantharidin) | New |
April 25, 2024 | *CC-0018 | Pompe Disease | Revised |
April 25, 2024 | *CC-0021 | Fabrazyme (agalsidase beta) | Revised |
April 25, 2024 | *CC-0046 | Zinplava (bezlotoxumab) | Revised |
April 25, 2024 | CC-0182 | Iron Agents | Revised |
April 25, 2024 | *CC-0068 | Growth Hormones | Revised |
April 25, 2024 | CC-0156 | Reblozyl (luspatercept) | Revised |
April 25, 2024 | *CC-0233 | Rebyota (fecal microbiota, live – jslm) | Revised |
April 25, 2024 | *CC-0020 | Natalizumab Agents (Tysabri, Tyruko) | Revised |
April 25, 2024 | CC-0064 | Interleukin-1 Inhibitors | Revised |
April 25, 2024 | CC-0026 | Testosterone Injectable | Revised |
April 25, 2024 | *CC-0247 | Beyfortus (nirsevimab) | Revised |
Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Blue Cross of California is contracted with L.A. Care Health Plan to provide Medi-Cal Managed Care services in Los Angeles County. Anthem is a registered trademark of Anthem Insurance Companies, Inc.
CABC-CD-048716-23-CPN48226
PUBLICATIONS: February 2024 Provider Newsletter
To view this article online:
Or scan this QR code with your phone